Psychopharmacology

New research highlights lithium's crucial role in brain health, revealing its potential to combat Alzheimer disease and enhance mental wellness.

FDA approves Tonmya, a groundbreaking fibromyalgia treatment, offering hope for pain relief after 15 years without new options.

Antidepressant treatment for late-life depression enhances cognitive functions like memory and learning, linking symptom relief to cognitive improvement.

Researchers uncover how serotonin receptor 5-HT1A influences drug interactions, paving the way for faster, targeted psychiatric treatments.

Explore the evolution and therapeutic potential of GLP-1, a key incretin in diabetes management and weight loss solutions.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

Serum drug levels provide crucial insights for optimizing psychiatric treatment, enhancing patient outcomes in cases of schizophrenia and OCD.

Benzodiazepines spark ongoing debate, balancing effective anxiety relief with addiction risks, as cultural attitudes shape their use and perception.

Research reveals significant risks of neonatal complications linked to in utero valproic acid exposure, emphasizing the need for careful management during pregnancy.

Valproic acid poses significant risks during pregnancy, including congenital malformations and neurodevelopmental disorders, necessitating careful treatment planning.

New analysis qualifies OPTIMUM study, finding antidepressant combinations more effective than switching for treatment resistant depression in elderly.

In this CME article, discover effective strategies for prescribing MAOIs in treating major depressive disorder.

Learn more about how serum drug levels enhance psychiatric treatment by providing critical insights into medication efficacy and patient outcomes.

How can we teach psychopharmacology in a way that engages today's digital-native psychiatry residents and enhances real-world application?

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

Roger S. McIntyre, MD, FRCPC, shares the backstory and pharmacology of incretins to better understand the role of GLP-1 RAs in psychiatry.

Learn more about how to best assess and treat tardive dyskinesia.

Now more than ever, capturing and scaling the ingredients that make for compelling and impactful teaching for trainees is vital to our future.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

In this CME article, learn more about the essential role of MAOIs in treating resistant depression and anxiety.

Phillip R. Muskin, MD, discusses the complexities of prescribing antipsychotics, emphasizing patient collaboration and the importance of evaluating treatment strategies.

Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.

Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.

Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.

Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.

Although there are topics in psychiatry that not exciting, Dr Ghaemi sees plenty of opportunities.

Poster presented at the APA Annual Meeting finds zuranolone effective for anhedonia associated with PPD.

Dr Nassir Ghaemi explores the long-term effects and safety of serotonin reuptake inhibitors, revealing benefits and potential risks.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

At the APA Annual Meeting, Dana Hilt, MD, PhD, explores the notion of precision psychiatry in depression treatment.